MedElevator
Войти в исследования Southern African journal of HIV medicine · 2026
Clinical presentation and treatment outcomes in a South African thrombotic thrombocytopenic purpura cohort with and without HIV.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vundla Nokubonga, Bailly Jenique, Brown Karryn, Oosthuizen Jenna, Verburgh Estelle
Аннотация
BACKGROUND: HIV is the most common cause of secondary thrombotic thrombocytopenic purpura (TTP) in South Africa.
OBJECTIVES: To assess the clinical presentations and outcomes of patients treated for HIV-associated and idiopathic TTP.
METHOD: We conducted a retrospective cohort study of patients consecutively diagnosed with TTP from 2010 to 2020 at Groote Schuur Hospital. Patients were identified by reviewing hospital and Western Cape Blood Services records. Kaplan-Meier curves and log-rank tests were used to evaluate remission rates, both overall and by HIV status and treatment group. Logistic regression models were used to identify predictors of remission and relapse.
RESULTS: One hundred and thirty-nine patients were included, 85.6% of whom were HIV positive. There were no significant differences in the TTP pentad features by HIV status. Most patients achieved remission (71.9%) with a median time of eight days. Remission occurred significantly earlier in those treated with fresh frozen plasma only, suggesting less severe disease (median = 8 days [interquartile range 6-10]), compared to those requiring plasma exchange, suggesting more severe disease (median = 12 days [interquartile range 8-22]). The overall mortality in the 10-year period was 38.9%, with 10.8% of the surviving patients relapsing after 6 months. There were no significant differences in remission status, time to remission, mortality or relapse by HIV status. All HIV-positive patients who relapsed had defaulted their antiretroviral therapy (ART).
CONCLUSION: HIV status did not affect patient outcomes in our cohort. ART is important in preventing HIV-associated TTP and relapse.
OBJECTIVES: To assess the clinical presentations and outcomes of patients treated for HIV-associated and idiopathic TTP.
METHOD: We conducted a retrospective cohort study of patients consecutively diagnosed with TTP from 2010 to 2020 at Groote Schuur Hospital. Patients were identified by reviewing hospital and Western Cape Blood Services records. Kaplan-Meier curves and log-rank tests were used to evaluate remission rates, both overall and by HIV status and treatment group. Logistic regression models were used to identify predictors of remission and relapse.
RESULTS: One hundred and thirty-nine patients were included, 85.6% of whom were HIV positive. There were no significant differences in the TTP pentad features by HIV status. Most patients achieved remission (71.9%) with a median time of eight days. Remission occurred significantly earlier in those treated with fresh frozen plasma only, suggesting less severe disease (median = 8 days [interquartile range 6-10]), compared to those requiring plasma exchange, suggesting more severe disease (median = 12 days [interquartile range 8-22]). The overall mortality in the 10-year period was 38.9%, with 10.8% of the surviving patients relapsing after 6 months. There were no significant differences in remission status, time to remission, mortality or relapse by HIV status. All HIV-positive patients who relapsed had defaulted their antiretroviral therapy (ART).
CONCLUSION: HIV status did not affect patient outcomes in our cohort. ART is important in preventing HIV-associated TTP and relapse.